Organization
Children's Oncology Group
53 clinical trials
6 abstracts
Clinical trial
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)Status: Active (not recruiting), Estimated PCD: 2019-03-31
Clinical trial
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)Status: Active (not recruiting), Estimated PCD: 2021-03-31
Clinical trial
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)Status: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsStatus: Recruiting, Estimated PCD: 2028-06-30
Clinical trial
A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS TumorsStatus: Completed, Estimated PCD: 2019-12-31
Clinical trial
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)Status: Active (not recruiting), Estimated PCD: 2017-09-30
Clinical trial
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyStatus: Recruiting, Estimated PCD: 2030-03-31
Clinical trial
Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative RhabdomyosarcomaStatus: Recruiting, Estimated PCD: 2030-12-31
Clinical trial
A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With RetinoblastomaStatus: Completed, Estimated PCD: 2017-06-30
Clinical trial
Letermovir Prophylaxis for Cytomegalovirus in Pediatric Hematopoietic Cell TransplantationStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS TumorsStatus: Active (not recruiting), Estimated PCD: 2022-09-30
Clinical trial
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic AcidStatus: Active (not recruiting), Estimated PCD: 2020-10-31
Clinical trial
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 YearsStatus: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and IrinotecanStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
A Phase I/II Study of Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia", Study ITCC-054/COG-AAML1921Status: Active (not recruiting), Estimated PCD: 2028-07-01
Clinical trial
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and LymphomaStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)Status: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk FeaturesStatus: , Estimated PCD: 2027-12-20
Clinical trial
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma PatientsStatus: Active (not recruiting), Estimated PCD: 2027-06-30
Clinical trial
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal RadiationStatus: Completed, Estimated PCD: 2016-09-27
Clinical trial
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk NeuroblastomaStatus: , Estimated PCD: 2015-07-28
Clinical trial
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell TumorStatus: Recruiting, Estimated PCD: 2029-12-21
Clinical trial
A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid TumorsStatus: Completed, Estimated PCD: 2009-06-01
Clinical trial
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET PatientsStatus: Active (not recruiting), Estimated PCD: 2019-06-30
Clinical trial
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 MutationsStatus: Active (not recruiting), Estimated PCD: 2027-09-30
Clinical trial
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular RetinoblastomaStatus: Active (not recruiting), Estimated PCD: 2018-06-30
Clinical trial
A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in ChildrenStatus: Completed, Estimated PCD: 2015-04-09
Clinical trial
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. the Same Therapy Without MethotrexateStatus: Active (not recruiting), Estimated PCD: 2016-12-31
Clinical trial
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute LeukemiasStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) With an Isocitrate Dehydrogenase-2 (IDH2) MutationStatus: Recruiting, Estimated PCD: 2030-12-31
Clinical trial
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized TrialStatus: , Estimated PCD: 2016-03-31
Clinical trial
A Phase II Trial Evaluating Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System GerminomasStatus: Not yet recruiting, Estimated PCD: 2033-11-04
Clinical trial
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2021-09-30
Clinical trial
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell TumorsStatus: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
Treatment of Children With Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)Status: Active (not recruiting), Estimated PCD: 2015-10-06
Clinical trial
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III StudyStatus: Completed, Estimated PCD: 2015-12-31
Clinical trial
Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms TumorStatus: , Estimated PCD: 2016-12-31
Clinical trial
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant LeukemiaStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Intravitreal Melphalan for Intraocular RetinoblastomaStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine StrategiesStatus: , Estimated PCD: 2016-03-01
Clinical trial
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) TrialStatus: Active (not recruiting), Estimated PCD: 2022-06-30
Clinical trial
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular RetinoblastomaStatus: Completed, Estimated PCD: 2010-01-01
Clinical trial
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy BackbonesStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)Status: Completed, Estimated PCD: 2014-12-31
Clinical trial
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Treatment for Very Low and Standard Risk Favorable Histology Wilms TumorStatus: Active (not recruiting), Estimated PCD: 2014-12-31
Clinical trial
A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and PrednisoneStatus: Completed, Estimated PCD: 2013-12-10
Abstract
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group,
Abstract
Relationship between ICOS and ICOS ligand RNA expression patterns with tumor type, tumor mutational burden, and clinically relevant immune checkpoints.Org: University of California San Diego, Moores Cancer Center, UC San Diego Health, La Jolla, CA, CanSino Biologics, Children's Oncology Group,
Abstract
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, NCI, Nihon Medi-Physics, National Cancer Institute, Vilnius, Lithuania, Institute for Clinical and Translational Research, Baylor College of Medicine,
Abstract
A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.Org: Memorial Sloan Kettering Cancer Center, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group, Mayo Clinic,
Abstract
Evaluation of local control strategies on patterns of treatment failure in patients with localized Ewing sarcoma treated on AEWS1031: A report from the Children’s Oncology Group.Org: Mayo Clinic Arizona, Phoenix, AZ, Moffitt Cancer Center, Children's Oncology Group, Public Health Institute, United Arab Emirates University, Alain, United Arab Emirates, Department of Radiation Oncology, University of Florida College of Medicine Jacksonville,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,